Monitor for DReAMzz study enrollment updates and eventual topline data readout, which will be the next major catalyst for IHL-42X. The stock may see modest positive momentum on this clinical progress, but with a $43M market cap and no revenue, the risk-reward is binary on Phase 3 outcomes.
Price Chart
Executive Summary
Incannex Healthcare announced the first patient dosed in the DReAMzz Phase 2 dose-optimization study of IHL-42X for obstructive sleep apnea. This milestone builds on positive Phase 2 RePOSA results showing AHI reductions up to 83% and FDA Fast Track designation. The filing is a routine clinical update with no financial data, representing a modest positive catalyst for the pipeline but not a transformative event for a $43M market cap company.
Key Facts
- First patient dosed in DReAMzz Phase 2 dose-optimization study of IHL-42X for obstructive sleep apnea.
- Prior Phase 2 RePOSA study showed statistically significant reductions in apnea-hypopnea index (AHI) vs placebo, with individual reductions up to 83%.
- IHL-42X has received FDA Fast Track designation.
- All 14 DReAMzz clinical trial sites have Institutional Review Board approval to conduct the study.
- The study is designed to optimize dose selection and inform the planned Phase 3 development program.
Financial Impact
No financial data provided in the filing. Clinical milestone with no revenue or earnings impact reported.
Risk Factors
- Clinical trial failure or disappointing DReAMzz results could significantly impair IHL-42X development.
- Cash burn rate and potential need for future dilutive financing given clinical-stage status.
- Regulatory delays or failure to meet FDA requirements for Phase 3 design.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-093244 |
| Document: 0001213900-26-093244-index.html | 0001213900-26-093244 |
| Document: 0001213900-26-093244.txt | 0001213900-26-093244 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $3.23 $3.18 | ▼ −1.55% | ▼ −3.49% | $2.68 (−17.03%) |
Aug 25, 2026 9w ago | 8-K | $3.75 $3.45 | ▼ −8.13% | ▼ −9.11% | $2.68 (−28.53%) |
Aug 11, 2026 11w ago | 8-K | $3.20 $3.23 | ▲ +0.94% | ▲ +2.00% | $2.68 (−16.25%) |
Jul 23, 2026 13w ago | Press Release | $3.16 $3.62 | ▲ +14.56% | ▲ +11.25% | $2.68 (−15.19%) |
Jul 23, 2026 13w ago | 8-K | $3.16 $3.62 | ▲ +14.56% | ▲ +11.25% | $2.68 (−15.19%) |
Jun 10, 2026 19w ago | Press Release | $3.91 $3.37 | ▼ −13.81% | ▼ −17.43% | $2.68 (−31.46%) |
Jun 10, 2026 19w ago | 8-K | $3.91 $3.37 | ▼ −13.81% | ▼ −17.43% | $2.68 (−31.46%) |
Jun 9, 2026 20w ago | 8-K | $3.67 $3.71 | ▲ +1.09% | ▼ −0.36% | $2.68 (−26.98%) |
May 14, 2026 23w ago | Press Release | $3.88 $3.83 | ▼ −1.29% | ▼ −0.43% | $2.68 (−30.93%) |
May 14, 2026 23w ago | 8-K | $3.88 $3.83 | ▼ −1.29% | ▼ −0.43% | $2.68 (−30.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers